Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa
Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical...
Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...
Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047
The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047,...
Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences...
Eyenovia Partners with Formosa Pharmaceuticals for Ophthalmic Therapeutics
US-based Eyenovia Inc., (NASDAQ: EYEN) has announced a strategic development and collaboration agreement with Taiwan-based...
Brii Biosciences Publishes Positive Phase II Results for HBV Treatment
China’s Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving the go-ahead from the National Medical Products...
Grand Pharma Completes First Atrial Fibrillation Treatment with HeartLight X3
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the successful completion of the first...
Zelgen’s ZG2001 and ZG0895 Clinical Trials Approved by NMPA
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that separate clinical trial filings for...
Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy
China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase...
Hygea Medtech Secures Series D Funding for Oncology Device Expansion
Hygea Medical Technology Co., Ltd, a leading minimally invasive device maker for oncology indications based...
CTI Acquires Vectoring Pharmatech to Expand Pharmacy CMC Research
China-based Centre Testing International Group Co., Ltd (CTI), a leading third-party testing and qualification services...
Shenzhen United Family Hospital Partners with GBA Medical Delegation
Shenzhen United Family Hospital has struck a partnership with a medical delegation from the Guangdong-Hong...
Vincentage Raises RMB 100 Million for Innovative Drug Development
Suzhou-based new drug developer Vincentage has reportedly raised close to RMB 100 million (USD 14.6...
Sequanta and Grandomics Collaborate on Ultra-High Throughput Sequencing Lab
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Grandomics Biosciences...
Luzhu Biotech Files for IPO in Hong Kong, Sponsored by CICC
Beijing Luzhu Biotechnology Co., Ltd, a leading human vaccine and therapeutic biologics maker, has made...
China’s NRDL Update: New Drugs Available for Online Procurement
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) drug procurement platform has released a notice stating that...
Mindray Launches First Wireless Handheld Ultrasound System, TE Air
China-based medical device firm Mindray (SHE: 300760) has announced the market launch of the firm’s...
Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...